<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="EN" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Clin Pharmacol</journal-id><journal-id journal-id-type="pmc-domain-id">279</journal-id><journal-id journal-id-type="pmc-domain">brjclinpharm</journal-id><journal-id journal-id-type="publisher-id">bcp</journal-id><journal-title-group><journal-title>British Journal of Clinical Pharmacology</journal-title></journal-title-group><issn pub-type="ppub">0306-5251</issn><issn pub-type="epub">1365-2125</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC2561111</article-id><article-id pub-id-type="pmcid-ver">PMC2561111.1</article-id><article-id pub-id-type="pmcaid">2561111</article-id><article-id pub-id-type="pmcaiid">2561111</article-id><article-id pub-id-type="pmid">18637887</article-id><article-id pub-id-type="doi">10.1111/j.1365-2125.2008.03230.x</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Pharmacokinetic Dynamic Relationships</subject></subj-group></article-categories><title-group><article-title>Population pharmacokinetic and pharmacodynamic analysis to support treatment optimization of combination chemotherapy with indisulam and carboplatin</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Zandvliet</surname><given-names initials="AS">Anthe S</given-names></name><xref ref-type="aff" rid="au1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Schellens</surname><given-names initials="JHM">Jan H M</given-names></name><xref ref-type="aff" rid="au2">2</xref><xref ref-type="aff" rid="au3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dittrich</surname><given-names initials="C">Christian</given-names></name><xref ref-type="aff" rid="au4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wanders</surname><given-names initials="J">Jantien</given-names></name><xref ref-type="aff" rid="au5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Beijnen</surname><given-names initials="JH">Jos H</given-names></name><xref ref-type="aff" rid="au1">1</xref><xref ref-type="aff" rid="au2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Huitema</surname><given-names initials="ADR">Alwin D R</given-names></name><xref ref-type="aff" rid="au1">1</xref></contrib><aff id="au1"><label>1</label><institution>Department of Pharmacy &amp; Pharmacology, The Netherlands Cancer Institute/Slotervaart Hospital</institution><addr-line>Amsterdam, the Netherlands</addr-line></aff><aff id="au2"><label>2</label><institution>Beta Faculty, Department of Pharmaceutical Sciences, Division of Biomedical Analysis, Section of Drug Toxicology, Utrecht University</institution><addr-line>Utrecht, the Netherlands</addr-line></aff><aff id="au3"><label>3</label><institution>Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital</institution><addr-line>Amsterdam, the Netherlands</addr-line></aff><aff id="au4"><label>4</label><institution>LBI-ACR Vienna and ACR&#8211;ITR Vienna, Centre for Oncology and Haematology, KFJ-Spital</institution><addr-line>Vienna, Austria</addr-line></aff><aff id="au5"><label>5</label><institution>Eisai Ltd</institution><addr-line>London, UK</addr-line></aff></contrib-group><author-notes><corresp id="cor1">Correspondence: Dr Anthe S Zandvliet, Louwesweg 6, 1066 EC Amsterdam, The Netherlands. Tel: +31 20 5124657 E-mail: <email>anthe.zandvliet@siz.nl</email></corresp></author-notes><pub-date pub-type="ppub"><month>10</month><year>2008</year></pub-date><pub-date pub-type="epub"><day>16</day><month>7</month><year>2008</year></pub-date><volume>66</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">172835</issue-id><fpage>485</fpage><lpage>497</lpage><history><date date-type="received"><day>28</day><month>1</month><year>2008</year></date><date date-type="accepted"><day>16</day><month>5</month><year>2008</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>10</month><year>2009</year></date></event><event event-type="pmc-live"><date><day>01</day><month>10</month><year>2009</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-03-16 03:25:14.567"><day>16</day><month>03</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2008 The Authors Journal compilation &#169; 2008 Blackwell Publishing Ltd</copyright-statement><copyright-year>2008</copyright-year></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="bcp0066-0485.pdf"/><abstract><sec><title>AIMS</title><p>Indisulam and carboplatin have shown synergistic activity in preclinical studies. In a dose escalation study of the combination, a treatment delay was frequently required in a 3-weekly regimen to allow recovery from myelosuppression from previous cycles. A 4-weekly regimen was better tolerated, but had a decreased dose-intensity which may compromise efficacy. The aims of this study were (i) to develop a pharmacokinetic&#8211;pharmacodynamic (PK&#8211;PD) model to describe the myelosuppressive effect of the combination, and (ii) to use this model to select a dosing regimen for Phase II evaluation.</p></sec><sec sec-type="methods"><title>METHODS</title><p>Sixteen patients were treated at four different dose levels of indisulam (1-h infusion on day 1) and carboplatin (30-min infusion on day 2). Pharmacokinetic data were analysed with nonlinear mixed effects modelling. A semiphysiological model describing chemotherapy-induced myelosuppression characterized the relationship between the pharmacokinetics and the haematological toxicity of indisulam and carboplatin. A simulation study was performed to evaluate the tolerability and dose-intensity for 3-weekly and 4-weekly treatment regimens.</p></sec><sec><title>RESULTS</title><p>The PK&#8211;PD model described the pharmacokinetics and the myelosuppressive effect of indisulam and carboplatin. The risk of a treatment delay at cycle 2 due to myelosuppression was unacceptably high (34&#8211;65%) in a 3-weekly regimen for various dose levels (350&#8211;600 mg m<sup>&#8722;2</sup> indisulam in combination with carboplatin to achieve an AUC of 4&#8211;6 mg min<sup>&#8722;1</sup> ml<sup>&#8722;1</sup>). This risk was acceptable for a 4-weekly regimen (9&#8211;24%), which is in line with the clinical study results.</p></sec><sec><title>CONCLUSIONS</title><p>This PK&#8211;PD study supports the selection of indisulam 500 mg m<sup>&#8722;2</sup> and a dose of carboplatin to achieve an AUC of 6 mg min<sup>&#8722;1</sup> ml<sup>&#8722;1</sup> in a 4-weekly regimen as the recommended dose for future studies.</p><p>
<boxed-text position="float"><sec><title>WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT</title><p><list list-type="bullet"><list-item><p>Chemotherapy with indisulam in combination with a standard dose of carboplatin was not well tolerated in a 3-weekly regimen in a Phase I dose escalation study.</p></list-item><list-item><p>Myelosuppression was the dose limiting toxicity.</p></list-item><list-item><p>This pharmacokinetic&#8211;pharmacodynamic (PK&#8211;PD) study was performed to suggest a dosing regimen for the combination therapy indisulam&#8211;carboplatin that is well tolerated in patients.</p></list-item></list></p></sec></boxed-text></p><p><boxed-text position="float"><sec><title>WHAT THIS STUDY ADDS</title><p>
<list list-type="bullet"><list-item><p>This PK&#8211;PD study supports the selection of indisulam 500 mg m<sup>&#8722;2</sup> and a dose of carboplatin to achieve an AUC of 6 mg min<sup>&#8722;1</sup> ml<sup>&#8722;1</sup> in a 4-weekly regimen as the recommended dose for future studies.</p></list-item></list></p></sec></boxed-text></p></sec></abstract><kwd-group><kwd>clinical oncology</kwd><kwd>pharmacokinetics</kwd><kwd>pharmacodynamics</kwd><kwd>neutropenia</kwd><kwd>thrombocytopenia</kwd><kwd>myelosuppression</kwd><kwd>indisulam</kwd><kwd>carboplatin</kwd><kwd>population analysis</kwd><kwd>NONMEM</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>